OakChart

ImageneBio Inc

IMAHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

3.72-0.09 (-2.36%)
2026-11-12 04:18 CET
Market cap
42.23 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-43.33 USD m
Free cash flow, TTM
-40.61 USD m
EPS diluted, TTM
-3.11
P/E
-
Compare

Price

IMA against its 20, 50 and 200-day averages
2050200beatmiss
4.006.008.00138K277KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IMAclose 3.7220-day 4.0550-day 4.45200-day 5.513.72

57.9% under the 52-week high of 8.84 on 11 Nov 2025. 52-week low 3.60 on 10 Nov 2026. Last 15 sessions, 23.6% high to low

Volume 0.29× normal · the line is the 50-bar volume average

Profile

IMA
52-week range, 2% of the way up
3.608.84

ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. It focuses on the development of new medicines with differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The company was founded in February 2016, and is headquartered in San Diego, CA.

Employees15
IPOMar 26, 2021
Beta0.89
ATR, 14d0.25
Rel volume0.29
Short float0.63%
Insider own36.07%
Inst own34.09%

Snapshot

6 groups

Valuation

Index-
Market Cap42.23M
Enterprise Value-77.58M
Income-43.33M
Sales0.00M
Book/sh10.29
Cash/sh11.15
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees15
IPOMar 26, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.36
P/C0.33
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio16.17
Current Ratio16.17
Debt/Eq0.05
LT Debt/Eq0.04
Option/ShortNo / Yes

Earnings

EPS (ttm)-3.11
EPS next Y-3.32
EPS next Q-0.96
EPS this Y63.98%
EPS next Y4.46%
EPS next 5Y28.07%
EPS past 3/5Y24.93% 8.22%
Sales past 3/5Y-62.86% -38.64%
EPS Y/Y TTM61.67%
Sales Y/Y TTM-100.00%
EPS Q/Q69.65%
Sales Q/Q-
EarningsNov 09 AMC
EPS/Sales Surpr.-13.13% -

Ownership

Insider Own36.07%
Insider Trans-0.08%
Inst Own34.09%
Inst Trans3.48%
ROA-28.56%
ROE-32.34%
ROIC-32.42%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-8.09%
SMA50-16.39%
SMA200-32.53%
Trades-

Technical

Shs Outstand12.46M
Shs Float7.26M
Short Float0.63%
Short Ratio3.44
Short Interest0.05M
52W High8.84 -57.92%
52W Low3.60 3.33%
Volatility7.67% 5.80%
ATR (14)0.25
RSI (14)30.62
Beta0.89
Rel Volume0.29
Avg Volume13.38K
Volume3,942

Performance

Perf Week-9.27%
Perf Month-12.26%
Perf Quarter-36.63%
Perf Half Y-35.53%
Perf YTD-46.09%
Perf Year-56.79%
Perf 3Y-78.77%
Perf 5Y-98.09%
Perf 10Y-
Recom2.00
Target Price18.00
Prev Close3.81
Price3.72
Change %-2.36%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Aug 21, 2026InitiatedHH.C. WainwrightBuy$28+652.7%
Nov 25, 2025ResumedWWedbushUnderperform$2-46.2%
Oct 24, 2025InitiatedLLeerink PartnersOutperform$30+706.5%

Peers

Mkt cap
TickerCompanyMkt cap
CNTBConnect Biopharma Holdings Ltd43.38M
NKTRNektar Therapeutics1.31B
ACRSAclaris Therapeutics Inc688.38M
ARQTArcutis Biotherapeutics Inc3.59B
ORKAOruka Therapeutics Inc7.27B
ZURAZura Bio Ltd137.75M
ALMSAlumis Inc883.74M
MLTXMoonLake Immunotherapeutics1.15B
AMGNAMGEN Inc253.21B
SNYSanofi ADR115.43B

Insider trading

4 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Yarema KristinChief Executive OfficerJul 25 '26Option Exercise0.0038,3760123,776Jul 28 04:05 PM
Lally Robert BPrincipal Accounting OfficerJul 16 '26Sale5.501,6719,19057,107Jul 20 09:47 PM
Lally Robert BPrincipal Accounting OfficerJul 17 '26Sale5.341,5258,14455,582Jul 20 09:47 PM
SLATTERY JOSEPH PDirectorDec 24 '25Buy5.9916,00095,84016,000Dec 29 04:46 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 18
  • ImageneBio Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York (GlobeNewswire)
  • ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • ImageneBio Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • ImageneBio Appoints Matt Robbins as General Counsel (GlobeNewswire)
  • ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York (GlobeNewswire)
  • ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update (GlobeNewswire) -10.49%
  • ImageneBio Announces $30 Million Private Placement (GlobeNewswire) +23.42%
  • ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update (GlobeNewswire)
  • ImageneBio to Participate in Leerink Global Healthcare Conference (GlobeNewswire)
  • ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer (GlobeNewswire)
  • ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.910-0.804-0.9100.000.004
2026Q22026-08-05-0.630-1.020-0.6300.000.002
2026Q12026-05-07-0.950-0.667-0.9470.000.003
2025Q42026-03-10-1.040-1.382-0.6180.270.003
2025Q32025-11-12-2.910-1.424-3.0050.000.002
2025Q22025-08-07-0.809-0.330-0.688-1.000.002
2025Q12025-05-08-2.040-1.972-2.1430.000.002
2023Q32023-11-09---4.7911.19--
2021Q22021-08-12---4.2443.55--
2021Q12021-05-13---3.2523.47--
2026Q4---0.965--0.004
2027Q1---0.747--0.003
2027Q2---0.797--0.003
2027Q3---0.887--0.003
2027Q4---1.003--0.003
2028Q1---0.653---2

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-12.240-13.288-40.5170.003.50
2025FY-9.640-5.567-9.6400.800.27
2026FY--3.473--0.00
2027FY--3.318--0.00
2028FY--3.588--0.00
2029FY--3.230--0.00
2030FY--3.813--0.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-104000.000.000.00
2026Q4S2026-11-094000.000.000.00
2026Q4S2026-08-204000.000.000.00
2026Q4S2026-08-053000.000.000.00
2026Q4S2026-05-083000.000.000.00
2026Q4S2026-03-113000.000.000.00
2026Q4S2026-03-102000.000.000.00
2026Q4S2025-11-241000.000.000.00
2026Q4R2026-11-10412-0.97-1.02-0.91
2026Q4R2026-11-09400-0.91-1.02-0.76
2026Q4R2026-10-19400-0.91-1.02-0.76
2026Q4R2026-08-20430-0.91-1.02-0.76
2026Q4R2026-08-05330-0.88-0.97-0.76
2026Q4R2026-07-22300-1.23-1.63-0.99

Estimate history

EPS, annual-13.678-5.629-14.813-11.38-22.802-19.6-40.517-9.645-3.107
Period20182019202020212022202320242025TTM
EPS, quarterly-2.545-2.269-2.143-0.688-3.005-0.618-0.947-0.63-0.912
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0.9913.7539.19430.98515.6189.163.50.80
Period20182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual2.9882.9882.9882.9983.0214.0221.4111.18212.456
Period20182019202020212022202320242025MRQ
Shares, quarterly4.0224.0224.0224.02211.18211.18211.27911.27912.456
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.803.509.1615.6230.989.1913.750.99
Cost of Goods Sold Incl. D&A1.091.031.531.022.03----
Gross Profit-1.09-0.231.978.1413.58----
Selling, General and Administrative Excl. Other48.5948.2238.9783.5684.4963.4152.4532.1241.46
Research and Development27.1728.5232.1158.6363.0445.9343.5824.8238.56
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-49.68-48.45-37.00-75.42-70.90-34.14-44.52-18.49-40.89
Interest Expense--0.000.000.000.00---
Unusual Expense0.000.000.000.000.000.000.000.000.00
Net Income Before Taxes-43.55-45.70-36.55-68.33-68.77-34.12-44.26-16.82-40.87
Income Taxes-0.23-0.350.01-0.160.000.000.000.000.00
Consolidated Net Income-43.33-45.35-36.57-68.17-68.77-34.12-44.26-16.82-40.87
Net Income From Continuing Operations-43.33-45.35-36.57-68.17-68.77-34.12-44.26-16.82-40.87
Net Income-43.33-52.40-48.38-68.17-68.77-34.12-44.26-16.82-40.87
EPS (Recurring)-2.53-9.64-40.52-19.60-22.80-11.38-14.81-5.63-13.68
EPS (Basic, Before Extraordinaries)-3.11-9.64-40.52-19.60-22.80-11.38-14.81-5.63-13.68
EPS (Diluted)-3.11-9.64-40.52-19.60-22.80-11.38-14.81-5.63-13.68
EBITDA-48.59-47.42-35.47-74.40-68.87-32.42-43.26-18.37-40.47
Non-Operating Income (Expense)6.122.750.457.092.140.020.261.680.03
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.7712.160.006.037.535.181.801.170.31
Price To Sales Ratio-46.856.718.986.1614.56---
Gross Margin--29.1256.4088.8686.98----
Operating Margin--6,056.38-1,057.14-823.33-453.99-110.18-484.22-134.46-4,130.71
Net Margin--6,549.38-1,382.40-744.17-440.29-110.10-481.36-122.28-4,127.78
Shares Outstanding12.4611.181.414.023.023.002.992.992.99
Market Capitalization42.2342.2379.1486.8996.44451.13473.95--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.180.180.170.560.000.090.090.09
Gross Profit-0.18-0.18-0.17-0.560.00-0.09-0.09-0.09
Selling, General and Administrative Excl. Other17.1311.6111.907.9426.598.359.2712.09
Research and Development11.276.675.963.2715.563.943.634.49
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-17.31-11.78-12.08-8.50-26.59-8.44-9.36-12.18
Interest Expense----0.100.000.000.00
Unusual Expense0.000.000.000.000.000.311.440.34
Net Income Before Taxes-15.60-10.16-10.61-7.18-24.85-2.75-8.59-9.07
Income Taxes0.020.020.01-0.28-0.070.010.030.05
Consolidated Net Income-15.62-10.18-10.62-6.91-24.78-2.77-8.62-9.12
Net Income From Continuing Operations-15.62-10.18-10.62-6.91-24.78-2.77-8.62-9.12
Net Income-15.62-10.18-10.62-6.91-25.62-2.77-8.62-9.12
EPS (Recurring)-0.91-0.63-0.95-0.62-3.01-0.63-1.89-2.21
EPS (Basic, Before Extraordinaries)-0.91-0.63-0.95-0.62-3.01-0.69-2.14-2.27
EPS (Diluted)-0.91-0.63-0.95-0.62-3.01-0.69-2.14-2.27
EBITDA-17.13-11.61-11.90-7.94-26.30-8.35-9.27-12.09
Non-Operating Income (Expense)1.711.621.471.321.846.002.203.45
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.320.720.690.0415.280.360.710.79
Shares Outstanding12.4611.2811.2811.1811.184.024.024.02
Market Capitalization42.2369.6855.9280.8291.1364.6761.7779.14

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments135.3512.12175.47156.95232.22162.4982.0818.16
Short Term Receivables1.300.080.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets3.640.273.203.064.303.483.121.82
Total Current Assets140.2912.47178.66160.01236.52165.9785.2019.98
Net Property, Plant & Equipment0.790.568.028.468.981.560.770.70
Total Investments and Advances0.000.941.280.872.390.870.000.00
Long-Term Note Receivable7.020.00------
Intangible Assets0.000.00--0.000.000.000.00
Other Assets4.881.964.132.920.000.000.000.00
Total Assets152.9815.92192.09172.26247.88168.4085.9720.68
Short Term Debt Incl. Current Port. of LT Debt2.267.813.561.911.850.190.000.00
Accounts Payable1.445.292.072.092.382.120.942.27
Other Current Liabilities7.534.118.5817.5022.9526.0223.361.56
Total Current Liabilities11.2317.2114.2121.5027.1928.3324.303.82
Long Term Debt7.730.247.183.795.13205.9878.8762.58
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities0.870.000.950.007.6835.1444.270.12
Total Liabilities19.8417.4522.3425.2940.00269.45147.4466.52
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.00178.010.000.000.000.000.000.00
Common Equity133.14-179.53169.76146.97207.88-101.05-61.46-45.84
Total Shareholders Equity133.14-1.53169.76146.97207.88-101.05-61.46-45.84
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity133.14-1.53169.76146.97207.88-101.05-61.46-45.84
Total Liabilities & Stockholders Equity152.9815.92192.09172.26247.88168.4085.9720.68
Book Value Per Share11.91-127.3442.2148.6469.34-33.82-20.57-15.34
Tangible Book Value Per Share11.91-127.3442.2148.6469.34-33.82-20.57-15.34
Full-Time Employees151043806733--
Price to Book Ratio0.360.630.560.612.172.33--
Return on Assets-30.80-35.16-37.42-32.73-16.39-34.80-31.54-
Return on Equity-35.01-43.47-43.04-38.76-63.87---
Return on Invested Capital-32.19--38.53-45.61-16.02-42.18-96.63-244.17
Quick Ratio12.490.7212.587.448.705.863.515.22
Current Ratio12.490.7212.587.448.705.863.515.22

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-43.33-45.35-36.57-68.17-68.77-34.12-44.26-16.82-40.87
Depreciation1.091.031.531.022.031.721.260.120.42
Other Funds (Non Cash)3.4515.6615.249.077.765.1812.941.1728.78
Funds from Operations-38.79-28.66-19.80-58.07-58.97-27.22-30.05-15.53-11.67
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.83-19.19-1.52-21.67-15.14-33.03-7.7763.450.06
Cash from Operating Activities-40.61-47.84-21.32-79.74-74.11-60.25-37.8347.93-11.61
Capital Expenditures0.000.000.00-0.41-1.43-1.76-0.77-0.32-0.30
Net Assets From Acquisitions0.00-5.210.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.970.000.000.000.000.000.00
Purchase or Sale of Investments-2.54-0.6010.1564.56-97.850.000.000.000.00
Purchase of Investments-33.52-10.400.00-90.05-216.340.000.000.000.00
Sale Or Maturity of Investments30.989.8010.15154.61118.480.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.003.690.0011.27
Cash from Investing Activities-2.54-5.8111.1264.14-99.28-1.762.92-0.3210.97
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock24.8965.84-0.5936.891.09131.74116.1816.320.00
Repurchase of Common Pref Stock0.000.000.00-0.660.000.000.000.000.00
Sale of Common Pref Stock24.8965.84-0.5937.561.09131.74116.1816.320.00
Proceedsfrom Stock Options24.7465.79-0.5937.420.00131.16116.1116.290.00
Issuance or Reduction of Debt, Net0.0015.007.500.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.0054.630.0039.090.000.000.000.000.00
Other Financing Activities Uses0.000.000.00-0.940.000.000.000.000.00
Cash from Financing Activities24.89135.476.9175.981.09131.74116.1816.320.00
Exchange Rate Effect-0.050.600.09------
Net Change in Cash-18.3182.41-3.2060.38-172.3069.7381.2863.93-0.64
Free Cash Flow-40.61-47.84-46.00-80.16-75.54-62.01-38.5947.61-11.91
Preferred Dividends (Cash Flow)--0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments126.60136.15117.21135.35142.5895.64
Short Term Receivables0.000.000.001.300.730.00
Inventories0.000.000.000.000.000.00
Other Current Assets4.004.964.803.644.223.37
Total Current Assets130.60141.11122.01140.29147.5399.01
Net Property, Plant & Equipment0.340.520.620.790.892.98
Total Investments and Advances0.000.000.000.000.000.90
Intangible Assets---0.000.00-
Other Assets6.127.858.334.884.9523.27
Total Assets142.54152.04136.68152.98160.88126.17
Short Term Debt Incl. Current Port. of LT Debt1.311.912.312.262.163.83
Accounts Payable0.930.980.571.442.080.51
Other Current Liabilities5.833.683.767.536.902.98
Total Current Liabilities8.076.576.6311.2311.147.32
Long Term Debt5.482.565.847.738.791.84
Provision for Risks Charges0.800.800.800.000.000.00
Other Liabilities0.050.040.080.871.111.09
Total Liabilities14.409.9713.3619.8421.0510.26
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity128.14142.07123.33133.14139.83115.91
Total Shareholders Equity128.14142.07123.33133.14139.83115.91
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity128.14142.07123.33133.14139.83115.91
Total Liabilities & Stockholders Equity142.54152.04136.68152.98160.88126.17
Book Value Per Share10.2912.6010.9311.9112.5128.82
Tangible Book Value Per Share10.2912.6010.9311.9112.5128.82
Full-Time Employees--1715--
Price to Book Ratio0.360.540.420.530.280.56
Return on Assets-28.56-37.73-33.70-29.25-29.23-21.68
Return on Equity-32.34-40.69-37.32-33.25-33.05-23.76
Return on Invested Capital-11.69-7.04-8.22-4.90-16.67-2.35
Quick Ratio16.1721.4718.3912.4913.2413.52
Current Ratio16.1721.4718.3912.4913.2413.52

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-15.62-10.18-10.62-6.91-27.05-2.77
Depreciation0.180.180.170.560.300.09
Other Funds (Non Cash)1.660.910.870.0113.450.95
Funds from Operations-13.78-9.10-9.58-6.33-13.30-1.73
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.260.02-5.22-0.88-13.34-1.69
Cash from Operating Activities-9.52-9.07-14.80-7.22-26.64-3.42
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.00-5.210.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-0.39-0.35-0.44-1.36-47.1239.95
Purchase of Investments-5.67-8.00-10.94-8.9121.70-6.00
Sale Or Maturity of Investments5.297.6510.507.55-68.8145.95
Other Uses0.000.000.000.0015.00-15.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.39-0.35-0.44-1.36-37.3324.95
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.00--0.00
Change in Capital Stock0.0828.05-3.240.0065.840.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.0828.05-3.240.0065.840.00
Proceedsfrom Stock Options-0.0328.05-3.280.0065.790.00
Issuance or Reduction of Debt, Net0.000.000.000.0015.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.0054.630.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.0828.05-3.240.00135.470.00
Exchange Rate Effect0.000.000.00-0.05--
Net Change in Cash-9.8218.63-18.48-8.6372.1521.53
Free Cash Flow-9.52-9.07-14.80-7.22-26.64-3.42

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 3.50M 2025: 800.00K
United States2024: 3.50M 2025: 800.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.63%0.0M7.3M13.57K
2026-10-150.85%0.1M7.3M13.88K
2026-09-300.45%0.0M7.3M12.60K
2026-09-150.48%0.0M7.3M11.78K
2026-08-310.55%0.0M7.2M12.05K
2026-08-140.68%0.0M7.2M12.68K
2026-07-315.28%0.4M7.3M23.10K
2026-07-155.26%0.4M7.5M32.07K
2026-06-305.40%0.4M7.5M341.95K
2026-06-155.29%0.4M7.5M342.11K
2026-05-296.13%0.4M7.3M349.37K
2026-05-156.13%0.4M7.3M353.11K
2026-04-306.72%0.5M7.0M354.36K
2026-04-158.60%0.6M6.8M355.61K
2026-03-315.56%0.4M7.0M37.13K
2026-03-135.43%0.4M7.0M44.61K
2026-02-275.18%0.4M7.3M51.84K
2026-02-135.06%0.4M7.3M53.56K
2026-01-304.99%0.4M7.7M48.97K
2026-01-154.97%0.4M7.7M60.14K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-098-KCurrent report2026-11-09SEC
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-11EFFECTEffectiveness filing by commission orderSEC
2026-08-11EFFECTEffectiveness filing by commission orderSEC
2026-08-06EFFECTEffectiveness filing by commission orderSEC
2026-08-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-05S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-05POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-08-05424B3SEC
2026-08-05S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-283Initial statement of beneficial ownership of securities2026-07-20SEC
2026-07-284Statement of changes in beneficial ownership of securities2026-07-25SEC
2026-07-23424B3SEC
2026-07-238-KCurrent report2026-07-20SEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-06-29424B3SEC
2026-06-268-KCurrent report2026-06-22SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-17424B3SEC
2026-06-178-KCurrent report2026-06-16SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-14SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070017.33K2
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-1295.84K100
2025-110000

Institutional holders

Manager% owned
BVF INC/IL9.40%
Blue Owl Capital Holdings LP7.77%
ORBIMED ADVISORS LLC7.70%
Cable Car Capital, LP6.62%
Omega Fund Management, LLC3.86%
RTW INVESTMENTS, LP2.83%
VANGUARD CAPITAL MANAGEMENT LLC2.71%
Trails Edge Capital Partners, LP2.39%
BML Capital Management, LLC1.77%
Monashee Investment Management LLC1.56%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND8.71%
VANGUARD EXTENDED MARKET INDEX FUND1.85%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.31%
Fidelity Extended Market Index Fund0.23%
iShares Micro-Cap ETF0.23%
Fidelity Series Total Market Index Fund0.06%
Fidelity Total Market Index Fund0.05%
Fidelity Nasdaq Composite Index Fund0.03%
VANGUARD BALANCED INDEX FUND0.03%
1290 VT Micro Cap Portfolio0.02%

OakChart. IMA. Cached 15 minutes.